Hospital Groups Secure Injunction of 340B Rebate Pilot Program in Federal Lawsuit

January 7, 2026

A federal court halted implementation of the controversial 340B Drug Pricing Program rebate model in late December as part of a lawsuit filed by the American Hospital Association and other healthcare organizations.

The ruling, issued by a U.S. District Court judge in Maine, requires the Health Resources & Services Administration to pause its newly proposed rebate model, which was to take effect on January 1. The plaintiffs, having secured an injunction, are expected to seek an order requiring HRSA to permanently discontinue implementation of the model.


The Arizona Medical Association is actively advocating for the discontinuation of the model, which poses a significant threat to local hospitals, physicians, and the patients they serve.


HRSA Reimagines 340B Program & Process


The program was designed to "test run" a model that replaces up-front drug discounts for safety-net hospitals with post-purchase rebates for at least one year. The pilot would require participating hospitals to submit a report to drugmakers within a 45-day window of the drug being dispensed.


The drugmaker would then be responsible for issuing a rebate payment within 10 days of receiving the report. The logistics of the process would largely be left to participating pharmaceutical companies, posing another concern for hospitals and healthcare professionals.


340B Program Background and Proposed Changes


Section 340B of the Public Health Service Act requires pharmaceutical manufacturers participating in Medicaid to sell outpatient drugs at discounted prices to health care organizations that care for many uninsured and low-income patients.

The program allows 340B hospitals to stretch federal resources in order to reduce the price of outpatient pharmaceuticals for patients and expand health services to the communities they serve. Hospitals often use 340B savings to offer free vaccines, provide services in mental health clinics, and implement medication management and community health programs.

The plaintiffs argue that, despite significant oversight from the HRSA and the program’s proven record of expanding access to vital patient care, critics want to drastically reduce the benefits that eligible hospitals and their patients receive by transitioning the program to rebate model.


Proposed "Rebate Model" Draws Sharp Criticism


The rebate model, announced in July 2025, was received with fierce opposition from the healthcare community, including the American Hospital Association, 340B Health, and other advocates. According to its opponents, the proposed model signifies a major "sea change" for hospitals, especially Federally Qualified Health Centers and sites operating on razor-thin financial margins, without appropriate stakeholder insight or logistical support.


Financial Impact on Safety-Net Hospitals


The legal challenge centers on concerns about overwhelming financial and administrative burdens the new program would place on 340B hospitals. Many of these facilities report operating on minimal profit margins while serving as critical healthcare access points in their communities, with some functioning as the sole care provider in their service areas.

According to AHA President and CEO Rick Pollack, the government acknowledged the program would fundamentally shift how the 340B program has functioned for more than three decades. The lawsuit contends that, despite the government's awareness, appropriate administrative procedures warranted by such a significant change were not followed.


Drugmakers Argue Program Extended Beyond Intent


Annual spending on drugs through the 340B program grew from $6.6 billion in 2010 to $43.9 billion in 2021, according to a nonpartisan analysis. Drugmakers point to this increase as evidence that the program has grown beyond federal lawmakers' original intent.


Hospitals & Stakeholders Voice Opposition


More than 1,000 340B hospitals and other stakeholders submitted concerns about the program during the development process. Many highlighted substantial costs and community impact associated with administering the rebate model. The plaintiffs assert HHS disregarded these documented concerns.



Sources: HFMA, American Hospital Association, HHS, and Fierce Healthcare

Abrazo Arizona Heart Hospital Launches Largest Expansion in Its History

By Admin User • August 7, 2026
Abrazo Arizona Heart Hospital Launches Largest Expansion in Its History Investment Expands Inpatient and Procedural Capacity to Meet Rising Demand for Cardiovascular Care The Abrazo Arizona Heart Hospital in Phoenix announced last week that it is undertaking the largest expansion in its history. The new construction will add inpatient and procedural capacity to serve more Arizonans in need of heart and vascular care. Meeting Arizona's Growing Demand for Heart Care Abrazo explained that the expansion is necessary to support Arizona's continued population growth, which is driving increased demand for cardiovascular services. The added capacity will allow the hospital to not only treat more patients requiring cardiac, vascular, and critical care, but also continue its participation in clinical research and innovation.  Part of a Multi-Year Investment Strategy In its press release, Abrazo describes the expansion as the latest phase of ongoing, multi-year investments intended to advance care and meet the evolving healthcare needs of communities across the state. The hospital did not report an anticipated completion date for the project. Source: Abrazo Health

Arizona Erases $1 Billion in Medical Debt for Nearly 671,000 Residents

By Admin User • August 7, 2026
Hobbs Highlights Milestone in Ongoing Partnership With Undue Medical Debt Gov. Katie Hobbs announced this week that more than $1 billion in medical debt has been erased for nearly 671,000 Arizonans, marking a significant milestone in the state's ongoing partnership with the nonprofit Undue Medical Debt. How the Program Works The initiative, first launched in 2024, purchases qualifying medical debt from hospitals and collection agencies for a fraction of its value before eliminating the debt entirely for eligible patients. Who Qualifies According to the governor's office, recipients do not need to apply for the program. It is available to Arizona residents who: Receive low- and moderate-income Have medical debt that represents a substantial share of their annual income A Flashpoint in the 2026 Election Season Healthcare affordability has been at the forefront of Arizona's political conversation as the 2026 election season intensifies. Supporters argue that relieving burdensome medical debt can improve: Families' financial stability Creditworthiness Willingness to seek needed healthcare Critics of similar programs have generally questioned whether debt forgiveness addresses the underlying drivers of rising healthcare costs or simply treats the financial consequences after care has been delivered. As debates continue over healthcare affordability and access, Arizona's medical debt relief initiative is expected to remain a prominent example in broader discussions about how states can help patients facing significant medical expenses.